Araceli Biosciences raises $11.2M for imaging and AI analysis systems to help speed drug discovery

Portland-based biotech company Araceli Biosciences raised $11.2 million in new funding to fuel the expansion of its high-content imaging technology and AI-powered analysis used to speed drug discovery. Araceli’s flagship platform is the Endeavor high content imaging system, which is designed for ultra high-throughput imaging — a process that measures the effects of chemical or genetic changes on cellular phenotypes. The imaging is used to gather data that provides a more thorough understanding of cellular responses to potential drug candidates. According to Araceli, traditional imaging systems lack speed and scalability, and Endeavor delivers results up to 40 times faster across… Read More

Apr 24, 2025 - 18:12

Araceli Biosciences raises $11.2M for imaging and AI analysis systems to help speed drug discovery

Portland-based biotech company Araceli Biosciences raised $11.2 million in new funding to fuel the expansion of its high-content imaging technology and AI-powered analysis used to speed drug discovery.

Araceli’s flagship platform is the Endeavor high content imaging system, which is designed for ultra high-throughput imaging — a process that measures the effects of chemical or genetic changes on cellular phenotypes.

The imaging is used to gather data that provides a more thorough understanding of cellular responses to potential drug candidates.

According to Araceli, traditional imaging systems lack speed and scalability, and Endeavor delivers results up to 40 times faster across a broad range of cellular assays. The company also says its AI-driven analysis software, called Clairvoyance, delivers rapid, actionable insights to streamline workflows, reduce experimental errors, and speed up drug discovery timelines.

“The future of AI-driven drug discovery and personalized medicine depends on imaging and analysis that happens in real time,” Matt Beaudet, CEO of Araceli Biosciences, said in a news release. “Minutes and seconds matter. The old model of waiting hours — or even days — for data is over. At Araceli, we’re building a platform that moves at the speed of science.”

Proceeds from the seed round will be used to scale operational infrastructure, advance market applications, advance the platform’s hardware and software for real-time analysis capabilities, and expand marketing and business development efforts.